Franklin Genomic Advancements Etf ETF Forecast

Buy or Hold candidate since May 27, 2026 Gain 4.89%

The Franklin Genomic Advancements ETF price gained 0.0813% on the last trading day (Monday, 22nd Jun 2026), rising from $36.04 to $36.07. During the last trading day the ETF fluctuated 0.86% from a day low at $36.07 to a day high of $36.38. The price has risen in 7 of the last 10 days and is up by 3.83% over the past 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 359 more shares were traded than the day before. In total, 366 shares were bought and sold for approximately $13.20 thousand.

The ETF lies in the middle of a wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the ETF is expected to rise 8.80% during the next 3 months and, with a 90% probability hold a price between $36.45 and $40.30 at the end of this 3-month period.

HELX Signals & Forecast

Mostly positive signals in the chart today. The Franklin Genomic Advancements ETF holds buy signals from both short and long-term Moving Averages giving a positive forecast for the ETF. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $35.72 and $34.44. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Tuesday, June 02, 2026, and so far it has risen 5.38%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Franklin Genomic Advancements has increased volume and follows the last lift in the price. This is considered to be a technical positive sign as volume should follow the price-formation. The very low volume increases the risk and reduces the other technical signals issued.

Support, Risk & Stop-loss for Franklin Genomic Advancements ETF

Franklin Genomic Advancements finds support from accumulated volume at $35.63 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

In general the ETF tends to have very controlled movements and with good liquidity the risk is considered very low in this ETF. During the last day, the ETF moved $0.310 between high and low, or 0.86%. For the last week the ETF has had daily average volatility of 0.615%.

Our recommended stop-loss: $34.23 (-5.11%) (This ETF has very low daily movements and this gives very low risk. There is a buy signal from a pivot bottom found 13 days ago.)

Trading Expectations (HELX) For The Upcoming Trading Day Of Tuesday 23rd

For the upcoming trading day on Tuesday, 23rd we expect Franklin Genomic Advancements ETF to open at $36.17, and during the day (based on 14 day Average True Range), to move between $35.79 and $36.35, which gives a possible trading interval of +/-$0.550 (+/-1.54%) up or down from last closing price. If Franklin Genomic Advancements ETF takes out the full calculated possible swing range there will be an estimated 1.54% move between the lowest and the highest trading price during the day.

With no resistance above and support from accumulated volume @ $35.63, some $0.440 (1.22%) from the current price of $36.07, our system finds the risk reward attractive.

Is Franklin Genomic Advancements ETF ETF A Buy?

Franklin Genomic Advancements holds several positive signals and is within a weak rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.

Current score: 6.075 Strong Buy Candidate Unchanged

Predicted Fair Opening Price

Predicted fair opening price on June 23, 2026 - $36.17 ( 0.286%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk